- Home
- FBIO vs ITRM Comparison
FBIO vs ITRM Comparison
Compare FBIO & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- ITRM
- Stock Information
- Founded
- FBIO 2006
- ITRM 2015
- Country
- FBIO United States
- ITRM Ireland
- Employees
- FBIO N/A
- ITRM N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- FBIO Health Care
- ITRM Health Care
- Exchange
- FBIO Nasdaq
- ITRM Nasdaq
- Market Cap
- FBIO 44.0M
- ITRM 37.7M
- IPO Year
- FBIO N/A
- ITRM 2018
- Fundamental
- Price
- FBIO $1.53
- ITRM $1.08
- Analyst Decision
- FBIO Strong Buy
- ITRM Strong Buy
- Analyst Count
- FBIO 3
- ITRM 1
- Target Price
- FBIO $21.00
- ITRM $5.00
- AVG Volume (30 Days)
- FBIO 247.1K
- ITRM 300.3K
- Earning Date
- FBIO 05-14-2025
- ITRM 05-12-2025
- Dividend Yield
- FBIO N/A
- ITRM N/A
- EPS Growth
- FBIO N/A
- ITRM N/A
- EPS
- FBIO N/A
- ITRM N/A
- Revenue
- FBIO $57,675,000.00
- ITRM N/A
- Revenue This Year
- FBIO $63.20
- ITRM N/A
- Revenue Next Year
- FBIO $66.70
- ITRM $150.10
- P/E Ratio
- FBIO N/A
- ITRM N/A
- Revenue Growth
- FBIO N/A
- ITRM N/A
- 52 Week Low
- FBIO $1.33
- ITRM $0.81
- 52 Week High
- FBIO $2.89
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- FBIO 46.68
- ITRM 32.84
- Support Level
- FBIO $1.45
- ITRM $1.05
- Resistance Level
- FBIO $1.64
- ITRM $1.16
- Average True Range (ATR)
- FBIO 0.13
- ITRM 0.08
- MACD
- FBIO 0.00
- ITRM -0.00
- Stochastic Oscillator
- FBIO 64.52
- ITRM 13.04
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.